Jubaan

Advanced Prescreening System for GI Disorders

Health Tech & Life Sciences
Active
Series A Yokne'am Illit Founded 2019
Total raised
$3.9M
Last: Seed 2024-01
Stage
Series A
Founded
2019
Headcount
11
HQ
Yokne'am Illit
Sector
Health Tech & Life Sciences

About

Jubaan provides an advanced pre-screening system able to detect early warning signals of Gastrointestinal disorders, specifically the presence of adenomas in the colon. Having studied Microbiomes, specifically those found in the oral cavity and on the tongue, Jubaan, through a non-invasive process, brings to market a practical & intuitive answer in the form of a device called Gixam™ aimed at early-stage pre-screening. More importantly, Gixam™ aims to dramatically improve compliance rates for pre-screening exams. With Gixam™ Jubaan is set to change the manner the prevention battle and control of Colon Cancer is waged.

Jubaan is currently part of the Alon Medtech incubator.

Funding history · 1 round · $3.9M total

2024-01
Seed Undisclosed

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is Jubaan's primary focus and what solution do they offer?
Jubaan specializes in advanced pre-screening for Gastrointestinal disorders, particularly detecting early warning signs of adenomas in the colon. They offer a non-invasive device called Gixam™ for early-stage pre-screening, aiming to improve compliance rates for such exams.
When was Jubaan founded and where is its headquarters located?
Jubaan was founded in November 2019 and is headquartered in Yokne'am Illit, Israel.
What is the current employee count for Jubaan?
Jubaan currently has 11 employees.
What is Jubaan's total funding raised to date?
Jubaan has raised a total of $3,940,000 USD.
When did Jubaan complete its last funding round and who was an investor?
Jubaan completed a Seed funding round in January 2024, with 4T Ventures as an investor. For full financing history, please refer to startupim.
Has Jubaan received any grants, and if so, from whom and when?
Yes, Jubaan received a grant of $790,000 USD from the IIA in August 2024.
What is Jubaan's current product stage?
Jubaan's product, Gixam, is currently in the clinical trial stage.
Which incubator is Jubaan currently part of?
Jubaan is currently part of the Alon Medtech incubator.
What technologies does Jubaan utilize in its solutions?
Jubaan utilizes Artificial Intelligence and Deep Learning in its solutions.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareDigital Medical Diagnostics
Technologies
Artificial IntelligenceDeep Learning
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B

Highlights

Verified

Tags

cancer-diagnosticscancernon-invasivedigital-healthcareartificial-intelligencedeep-learningimaginggastroenterologyearly-detection